Ireland HIV Therapeutics Market Analysis Report [2022-30]

Ireland HIV Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Ireland HIV therapeutics market will reach a value of $xx Mn from $xx Mn in 2022, growing at a CAGR of xx% during 2022-2030. The market is primarily dominated by local players such as Gilead Sciences, Pfizer, and Gilead Sciences. The market is driven by government policies and non-governmental organizations’ initiatives for the management of HIV infections in the country. The HIV therapeutics market in Ireland is segmented by type, product, and geography, end user, and distribution channel.

ID: IN10IEPH037 CATEGORY: Pharmaceuticals GEOGRAPHY: Ireland AUTHOR: Dr. Vishwa Modhia

Buy Now

Ireland HIV Therapeutics Market Analysis Summary

By 2030, it is anticipated that the Ireland HIV therapeutics market will reach a value of $xx Mn from $xx Mn in 2022, growing at a CAGR of xx% during 2022-2030.

Ireland is an island nation located in Western Europe, northwest of the United Kingdom. The number of HIV/AIDS-related deaths in Ireland will reach 100 in 2020, according to the most recent WHO data. With a death rate of 0.15 per 100,000 people when adjusted for age, Ireland is ranked 150th in the world. With 7800 HIV cases in 2020, Ireland's adult prevalence of HIV/AIDS was 0.3% in 2021, placing it in 78th place globally.

In 2019, Ireland's GDP was allocated to healthcare at 7.1%. HIV Ireland is the organization that manages HIV/AIDS cases in Ireland. More than 750 cases of HIV have been reported in 2022, according to statistics released by the Health Protection Surveillance Centre. This is more than twice as many cases as were reported during the same time period in 2021.

Market Dynamics

Market Growth Drivers

The Irish government funds and supports HIV care, including ART access, which has boosted the uptake of these medications. In order to ensure that Ireland can fulfill its international commitment to stop new HIV transmissions, the government organization HIV Ireland recently called for increased funding for all national sexual health services, including personnel and resources. These elements may stimulate Ireland’s market for HIV therapeutics.

Market Restraints

Although the quality of healthcare in Ireland is generally high, waiting lists and costs limit access to services. Access to testing, care, and treatment for people living with HIV continues to be severely hampered in Ireland due to stigma and discrimination.

Competitive Landscape

Key Players

Bristol-Myers Squibb
Pfizer
Gilead Sciences
Merck & Co
ViiV Healthcare
Roche
AstraZeneca

Recent Notable Updates

October 2020: Due to the ongoing Covid-19 pandemic, one of Ireland's biggest suppliers of HIV preventive medication has permanently closed. All of the current users of the Gay Men's Health Service (GMHS) were urged to schedule appointments with alternative PrEP (Pre-Exposure Prophylaxis) services yesterday.

Healthcare Regulations and Reimbursement Policies

The approval and distribution of antiretroviral drugs used to treat HIV are governed by the Health Products Regulatory Authority (HPRA), a regulatory body in Ireland. The HPRA is solely in charge of regulating pharmaceuticals and medical devices in Ireland. The HPRA reviews antiretroviral drugs for efficacy, quality, and safety before deciding whether to approve them for use in Ireland. The HPRA works closely with the European Medicines Agency (EMA), as well as other national and international regulatory bodies, to ensure the effectiveness and safety of antiretroviral medications for use in Ireland.

The Health Service Executive (HSE), Ireland's public health system, is primarily responsible for paying for antiretroviral medications used to treat HIV. The government funds the HSE, which is in charge of offering healthcare services to Ireland's citizens. The majority of antiretroviral medications can be obtained from the HSE and are given without charge to patients who have a prescription from a healthcare professional. The cost of antiretroviral medications in Ireland may also be covered by private health insurance in addition to the public healthcare system.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

HIV Therapeutics Segmentation

By Types (Revenue, USD Billion):

Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
Coreceptor Antagonists
Entry and Fusion Inhibitors
Integrase Inhibitors
Protease Inhibitors (PIs)
Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.